Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia

BMC Psychiatry

Evangelos C Alexopoulos²  Eleftherios Moratis¹  Angeliki Mestousi¹  Giorgos Merekoulias²  Evangelia Giourou²  Eleni Jelastopulu² 

[1] Department of Medical Affairs, Janssen-Cilag, Athens, Greece;Department of Public Health, School of Medicine, University of Patras, Rio-Patras GR-26500, Greece

关键词: Reliability;    Validity;    Social functioning;    Correlation;    PANSS;    PSP;   

Others  :  1123469
DOI  :  10.1186/1471-244X-14-197

 received in 2014-01-08, accepted in 2014-06-30,  发布年份 2014

【 摘 要 】

Background

Psychosocial dysfunction is one of schizophrenia’s core features, often leading to a deprecation of independent living and significant failure to maintain a competent quality of life. Cognitive and occupational performance as well as psychosocial functioning is moreover recognized as determinants of treatment response. Therefore, the elaboration of measures regarding social performance besides scales that assess psychopathology is essential. The Personal and Social Performance (PSP) scale has been found to be as much valid as reliable for assessing social functioning in the acute and stable stage of schizophrenia. The aim of this study was to estimate the correlation between the PSP and Positive and Negative Syndrome Scale (PANSS) (convergent validity) in patients with schizophrenia during routine clinical practice.

Methods

A longitudinal study with a six-month follow-up is presented. Correlation between the PSP scale and the Positive and Negative Syndrome Scale (PANSS) was conducted in a Greek sample of 2010 patients with schizophrenia in outpatient setting in two successive visits. PANSS and PSP scales were used for the assessment of psychopathological symptoms and social and personal functioning.

Results

The PSP subscales scores were well correlated with each other with Spearman correlation coefficients (r) ranging from 0.56 to 0.76 on both visits in three out of the four main areas, whereas in the category of “disturbing and aggressive behavior” the correlations were lower but still significant. Furthermore, total PSP score showed high association to PANSS total score in the first (r = -0.59) as well as in the second visit (r = -0.50). Regression analysis showed that one point decrease of PANSS’s total score is associated with a 0.42 points increase on the PSP scale. PSP and PANSS scales exhibited high convergent validity.

Conclusions

The PSP could provide additional valuable information in the assessment of schizophrenia related social functioning and treatment response.

【 授权许可】

   
2014 Jelastopulu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bottlender R, Strauss A, Moller HJ: Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. Schizophr Res 2010, 116:9-15.
• [2]Hafner H, Loffler W, Maurer K, Hambrecht M, An der Heiden W: Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999, 100:105-118.
• [3]Stanghellini G, Ballerini M: Dis-sociality: the phenomenological approach to social dysfunction in schizophrenia. World Psychiatry 2002, 1:102-106.
• [4]Association AP: Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association; 1994.
• [5]Burns T, Patrick D: Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007, 116:403-418.
• [6]Brune M, Schaub D, Juckel G, Langdon R: Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology. Psychiatry Res 2011, 190:9-17.
• [7]Corcoran CM, Kimhy D, Parrilla-Escobar MA, Cressman VL, Stanford AD, Thompson J, David SB, Crumbley A, Schobel S, Moore H, Malaspina D: The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis. Psychol Med 2011, 41:251-261.
• [8]Smith TE, Hull JW, Huppert JD, Silverstein SM: Recovery from psychosis in schizophrenia and schizoaffective disorder: symptoms and neurocognitive rate-limiters for the development of social behavior skills. Schizophr Res 2002, 55:229-237.
• [9]Weinberg D, Shahar G, Davidson L, McGlashan TH, Fennig S: Longitudinal associations between negative symptoms and social functioning in schizophrenia: the moderating role of employment status and setting. Psychiatry 2009, 72:370-381.
• [10]Rocca P, Montemagni C, Castagna F, Giugiario M, Scalese M, Bogetto F: Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:373-379.
• [11]Brune M: Emotion recognition, ‘theory of mind’, and social behavior in schizophrenia. Psychiatry Res 2005, 133:135-147.
• [12]Stefanopoulou E, Lafuente AR, Saez Fonseca JA, Huxley A: Insight, global functioning and psychopathology amongst in-patient clients with schizophrenia. Psychiatr Q 2009, 80:155-165.
• [13]MacEwan TH, Athawes RW: The Nithsdale Schizophrenia Surveys. XV. Social adjustment in schizophrenia: associations with gender, symptoms and childhood antecedents. Acta Psychiatr Scand 1997, 95:254-258.
• [14]Rocca P, Pulvirenti L, Montemagni C, Rasetti R, Rocca G, Bogetto F: Basic symptoms in stable schizophrenia: relations with functioning and quality of life. Clin Neuropsychiatry 2010, 7:100-110.
• [15]Karow A, Naber D: Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 2002, 162:3-10.
• [16]Juckel G, Morosini PL: The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry 2008, 21:630-639.
• [17]Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
• [18]Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I: Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009, 25:325-338.
• [19]Juckel G, Schaub D, Fuchs N, Naumann U, Uhl I, Witthaus H, Hargarter L, Bierhoff HW, Brune M: Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res 2008, 104:287-293.
• [20]Nasrallah H, Morosini P, Gagnon DD: Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res 2008, 161:213-224.
• [21]Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90:147-161.
• [22]Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A: Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-1370.
• [23]Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007, 93:117-130.
• [24]Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ: Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr 2005, 10:1-13. discussion 14–15
• [25]Franz M: Possibilities and limitations of the use of quality of life as outcome-indicator in schizophrenic patients. Psychiatr Prax 2006, 33:317-322.
• [26]Angermeyer MC, Holzinger A, Matschinger H: Quality of life–what it means to me… Results of a survey among schizophrenic patients. Psychiatr Prax 1999, 26:56-60.
• [27]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
• [28]Lykouras E, Botsis A, Oulis P: The Positive and Negative Syndrome Scale (PANSS) [in Greek]. Tsiveriotis Ed: Athens, Greece; 1994.
• [29]Apiquian R, Elena Ulloa R, Herrera-Estrella M, Moreno-Gomez A, Erosa S, Contreras V, Nicolini H: Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophr Res 2009, 112:181-186.
• [30]Fleischhacker WW, Kemmler G: The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology 2007, 32:2435-2436.
• [31]Eack SM, Newhill CE: Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull 2007, 33:1225-1237.
• [32]Woon PS, Chia MY, Chan WY, Sim K: Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:463-468.
• [33]Rocca P, Giugiario M, Montemagni C, Rigazzi C, Rocca G, Bogetto F: Quality of life and psychopathology during the course of schizophrenia. Compr Psychiatry 2009, 50:542-548.
• [34]Tianmei S, Liang S, Yun’ai S, Chenghua T, Jun Y, Jia C, Xueni L, Qi L, Yantao M, Weihua Z, Hongyan Z: The Chinese version of the Personal and Social Performance Scale (PSP): validity and reliability. Psychiatry Res 2011, 185:275-279.
• [35]Lindenmayer JP, Bernstein-Hyman R, Grochowski S: A new five factor model of schizophrenia. Psychiatr Q 1994, 65:299-322.
• [36]Lancon C, Auquier P, Nayt G, Reine G: Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 2000, 42:231-239.
• [37]Hough D, Nuamah IF, Lim P, Sampson A, Gagnon DD, Rothman M: Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis. J Clin Psychopharmacol 2009, 29:496-497.